Simplify the topic 5 fluorouracil from anticancer Lippincott
Reading File
Now let me search the Lippincott anticancer section for 5-fluorouracil:
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Found it - Lippincott Illustrated Reviews Pharmacology has a dedicated "D. 5-Fluorouracil" section. Let me read it fully:
Reading File
Reading File
I got the core 5-FU content from offset 2622 onwards. Let me read the full 5-FU section more carefully - I need what was truncated in the first read (the mechanism, pharmacokinetics, adverse effects):
Reading File
Reading File
I noticed the adverse effects section was truncated. Let me get it:
Reading File
It looks like the adverse effects section for 5-FU specifically wasn't fully captured. Let me check what the truncation said earlier - I need to look at the original read at offset 2629 more carefully. Let me also fetch the diagram image:
Loading Image
Finding Sources
Reading File
I now have all the information I need from Lippincott to write a comprehensive, simplified breakdown. Here is the full explanation:
5-Fluorouracil (5-FU) - Simplified from Lippincott Illustrated Reviews: Pharmacology
Source: Lippincott Illustrated Reviews: Pharmacology - Anticancer Drugs (Chapter 37)
What is 5-FU?
5-Fluorouracil is a pyrimidine antimetabolite - it mimics the natural pyrimidine uracil but has a fluorine atom instead of hydrogen at position 5 of the uracil ring. This small change makes it a "fake" building block that poisons the DNA-making machinery.
- It is itself inactive (a prodrug that needs intracellular conversion)
- It is cell cycle specific - works in the S phase
Clinical Uses
5-FU is used mainly for slow-growing solid tumors:
| Tumor | Notes |
|---|---|
| Colorectal carcinoma | Most common use; often combined with leucovorin + irinotecan |
| Breast carcinoma | Part of combination regimens |
| Gastric carcinoma | |
| Pancreatic carcinoma | |
| Ovarian carcinoma | |
| Superficial basal cell carcinoma | Applied topically |
Mechanism of Action (Step by Step)
This is the most important part - understand the pathway:
Step 1: 5-FU enters the cancer cell via a carrier-mediated transport system (not by passive diffusion).
Step 2 (Activation inside the cell):
- 5-FU → 5-FUR (5-fluorouridine) via uridine phosphorylase
- 5-FUR → 5-FUMP (monophosphate) → 5-FUDP → then reduced by ribonucleotide reductase to form 5-FdUMP (5-fluorodeoxyuridine monophosphate)
Alternatively, 5-FU can go via phosphoribosyl transferase directly to 5-FUMP.
Step 3 (The Kill):
- 5-FdUMP is the active metabolite
- It competes with dUMP (deoxyuridine monophosphate) for the enzyme thymidylate synthase
- Thymidylate synthase normally converts dUMP → dTMP (thymidine), an essential DNA precursor
- 5-FdUMP inhibits thymidylate synthase → no dTMP → no thymidine → "thymidine-less death"
Two additional killing mechanisms:
- 5-FU is incorporated into RNA - disrupts RNA processing and function
- Low levels are incorporated into DNA - a glycosylase excises the 5-FU → DNA strand damage
Key trick for exams: 5-FU blocks DNA synthesis by killing thymidylate synthase. Remember the phrase "thymidine-less death."
Leucovorin (Folinic Acid) - Potentiator
Leucovorin (folinic acid) is added to enhance 5-FU toxicity, not to rescue it (contrast with methotrexate where leucovorin rescues).
- Leucovorin stabilizes the binding of 5-FdUMP to thymidylate synthase (ternary complex becomes more stable)
- Standard regimen for advanced colorectal cancer: Irinotecan + 5-FU + Leucovorin (FOLFIRI)
Pharmacokinetics
| Parameter | Detail |
|---|---|
| Route | IV (oral not used - severe GI toxicity); Topical for skin cancer |
| Distribution | Penetrates well into all tissues including CNS |
| Metabolism | Rapidly metabolized in liver, lung, kidney |
| Elimination | Inactive metabolites excreted in urine |
| Key enzyme | Dihydropyrimidine dehydrogenase (DPD) - major catabolic enzyme |
DPD - Important Clinical Point
- High DPD levels = faster 5-FU breakdown = decreased bioavailability (treatment failure)
- DPD levels vary up to sixfold between individuals
- DPD deficiency = 5-FU accumulates = severe toxicity: pancytopenia, mucositis, life-threatening diarrhea
Adverse Effects
From the Lippincott summary table:
| Adverse Effect | Notes |
|---|---|
| Diarrhea | Very common, dose-limiting |
| Severe mucositis | Stomatitis (oral ulcers) |
| Myelosuppression | Especially with bolus dosing |
| Hand-foot syndrome | More common with continuous infusion (also called palmar-plantar erythrodysesthesia - erythematous desquamation of palms and soles) |
| Alopecia | Hair loss |
| Coronary vasospasm | Unique cardiac toxicity - rare but important |
Bolus vs. Infusion memory trick: Bolus = Bone marrow suppression (myelosuppression). Continuous infusion = Cutaneous (hand-foot syndrome).
Monitoring: CBC, renal function, hepatic function, diarrhea
Resistance Mechanisms
Resistance to 5-FU occurs via:
- Decreased conversion to active 5-FdUMP (enzyme deficiencies in activation pathway)
- Amplification or mutation of thymidylate synthase (less drug binding)
- Increased DPD activity (faster drug catabolism)
Capecitabine - The Oral Prodrug of 5-FU
| Feature | Detail |
|---|---|
| Classification | Fluoropyrimidine carbamate; oral prodrug of 5-FU |
| Uses | Colorectal cancer, metastatic breast cancer |
| Activation | Absorbed orally → converted to 5-FU by thymidine phosphorylase (concentrated in tumors) |
| Advantage | Tumor-specific activation (thymidine phosphorylase is higher in tumors) |
| Key difference | Hand-foot syndrome MORE common vs 5-FU; nausea, diarrhea, stomatitis, neutropenia less common |
Quick Summary Table
| Feature | 5-FU |
|---|---|
| Class | Pyrimidine antimetabolite |
| Prodrug? | Yes - activated intracellularly |
| Active metabolite | 5-FdUMP |
| Target enzyme | Thymidylate synthase |
| Cell cycle phase | S phase |
| Route | IV (topical for skin) |
| Potentiator | Leucovorin (stabilizes inhibition) |
| Unique toxicity | Coronary vasospasm |
| Bolus toxicity | Myelosuppression |
| Infusion toxicity | Hand-foot syndrome |
| DPD deficiency risk | Severe toxicity (pancytopenia, diarrhea) |
| Oral prodrug | Capecitabine |
Create a visual poster explaining the thymidylate synthase pathway and how 5-FU blocks it
Generating Image
A detailed educational pharmacology poster titled "5-Fluorouracil (5-FU): Blocking the Thymidylate Synthase Pathway" showing: TOP SECTION - Drug Entry: - 5-FU molecule (uracil ring with F atom at position 5, labeled) entering a cancer cell via "Carrier-mediated transport" MIDDLE SECTION - Activation Pathway (left to right flow with arrows): - 5-FU → (uridine phosphorylase) → 5-FUR → 5-FUMP → (uridine kinase) → 5-FUDP → (ribonucleotide reductase) → 5-FdUMP [highlighted in red as the ACTIVE METABOLITE] - Alternative path: 5-FU → (phosphoribosyl transferase) → 5-FUMP - Branch showing 5-FUTP incorporated into RNA (labeled "RNA disruption") BOTTOM SECTION - The Block (most prominent part): - Large diagram showing the NORMAL pathway: dUMP + N5,N10-methylene-THF → (thymidylate synthase) → dTMP → DNA synthesis - 5-FdUMP shown with a large RED BLOCK/STOP symbol competing with dUMP at thymidylate synthase - Thymidylate synthase enzyme shown as a large shape with both dUMP and 5-FdUMP trying to bind - The dTMP production is BLOCKED → "NO dTMP" → "THYMIDINE-LESS DEATH" in bold red - Leucovorin/folinic acid shown stabilizing the 5-FdUMP + thymidylate synthase complex (labeled "Leucovorin ENHANCES inhibition") RIGHT SIDE PANEL - Clinical boxes: - Green box: "Uses: Colorectal, Breast, Gastric, Pancreatic, Ovarian cancers; Topical: Basal cell carcinoma" - Orange box: "Adverse Effects: Myelosuppression (bolus), Hand-foot syndrome (infusion), Mucositis, Diarrhea, Coronary vasospasm" - Blue box: "DPD Deficiency → Severe toxicity: Pancytopenia, Mucositis, Life-threatening diarrhea" Color scheme: Clean white background, blue for normal pathway, red for 5-FU and its blocks, green for clinical info. Medical textbook style with clear labels and arrows.
Here is your visual poster covering the full 5-FU mechanism. It walks through:
- Entry - carrier-mediated transport into the cancer cell
- Activation pathway - 5-FU → 5-FdUMP (the active metabolite) via multiple enzymatic steps, plus the branch into RNA incorporation
- The block - 5-FdUMP competing with dUMP at thymidylate synthase, stopping dTMP production and causing "thymidine-less death"
- Leucovorin - shown stabilizing the inhibitory complex to enhance 5-FU's effect
- Clinical side panel - uses, adverse effects, and the DPD deficiency warning
A quick memory anchor for the poster: the whole purpose of the pathway is to make dTMP for DNA. 5-FU disguises itself as a substrate, sneaks into the enzyme's active site, and permanently jams it - no dTMP, no DNA replication, cell dies.
analyse_media
analyse_media
I can see both pages clearly. Now let me pull the full content from the Lippincott textbook for these drugs to give an accurate, complete simplified answer:
Reading File
Reading File
I have all the content needed. The two images show pages from what appears to be Lippincott's Pharmacology (the user's physical book, which is a different edition - the chapter is Chapter 35 in their copy vs. Chapter 37 in the digital version). The content is the same. Let me now deliver a thorough simplified breakdown of both pages.
Antitumor Antibiotics - Simplified from Lippincott (Chapter 35)
These pages cover the antitumor antibiotic class of anticancer drugs.
Overview - What are Antitumor Antibiotics?
Despite the name "antibiotics," these drugs are used for cancer, not infections. They work by interacting with DNA in multiple ways:
| Mechanism | Example |
|---|---|
| DNA intercalation (inserting between base pairs) | Doxorubicin |
| Inhibit topoisomerase I and II | Doxorubicin |
| Produce free radicals → DNA damage | Doxorubicin, Bleomycin |
Key rule: Almost all antitumor antibiotics are cell cycle NON-specific - they kill cells regardless of which phase they're in. Exception: Bleomycin (G₂ phase specific).
A. Anthracyclines
Members:
- Doxorubicin (most important) - hydroxylated analog of daunorubicin
- Daunorubicin - used in acute leukemias
- Idarubicin - 4-demethoxy analog of daunorubicin; acute leukemias
- Epirubicin - used in breast cancer protocols
- Mitoxantrone - AML and prostate cancer
Doxorubicin - The Most Important One
Clinical Uses
- Sarcomas (bone/soft tissue)
- Breast cancer, many solid tumors (in combination)
- Leukemias and lymphomas
1. Mechanism of Action (3 ways it kills)
| Mechanism | What happens |
|---|---|
| DNA intercalation | Doxorubicin inserts itself between DNA base pairs → blocks DNA and RNA synthesis |
| Topoisomerase II inhibition | Prevents DNA repair → DNA fragments accumulate |
| Free radical generation | Doxorubicin + cytochrome reductase → superoxide/H₂O₂ → lipid peroxidation, DNA strand scission, oxidation of bases |
2. Pharmacokinetics
| Parameter | Detail |
|---|---|
| Route | IV only (inactivated in GI tract) |
| Extravasation risk | Serious - causes tissue necrosis if it leaks |
| Distribution | Wide - binds plasma proteins and tissues; does NOT cross BBB or enter testes |
| Metabolism | Extensive hepatic metabolism - dose adjust in liver disease |
| Excretion | Biliary (major route) |
| Urine color | Red discoloration (drug's dark red color) |
3. Adverse Effects
| Adverse Effect | Notes |
|---|---|
| Cardiotoxicity ⚠️ | Most serious - IRREVERSIBLE, dose-dependent; causes LV dysfunction and heart failure |
| Mechanism of cardiotoxicity | Free radical generation + lipid peroxidation in cardiac muscle |
| Adding trastuzumab | Increases risk of heart failure (avoid combining) |
| Prevention | Liposomal doxorubicin (less cardiotoxic) OR add dexrazoxane (iron chelator) |
| Myelosuppression | Bone marrow suppression |
| N/V/D, alopecia, stomatitis | General chemotherapy toxicities |
Memory trick for cardiotoxicity: "Doxo-rubiCIN damages the cardiaCIN" - the free radicals generated are the same ones that cause cardiac damage.
B. Bleomycin
Uses:
- Testicular cancers
- Hodgkin lymphoma
1. Mechanism of Action
Bleomycin-Fe²⁺ complex → oxidized to bleomycin-Fe³⁺ → releases electrons → reacts with O₂ → superoxide/hydroxyl radicals → attack phosphodiester bonds → DNA strand breaks + chromosomal aberrations
Simple version: Bleomycin is a copper/iron-chelating glycopeptide that creates damaging free radicals next to DNA.
Cell cycle specific: G₂ phase (unlike other antitumor antibiotics!)
2. Pharmacokinetics
- Given by multiple routes
- Bleomycin-inactivating enzyme (hydrolase) is high in liver and spleen but LOW in lung and skin → explains why toxicity concentrates there
- Excreted unchanged in urine → dose adjust in renal failure
3. Adverse Effects
| Adverse Effect | Notes |
|---|---|
| Pulmonary toxicity ⚠️ | Most serious - progresses from cough/rales → infiltrate → fatal pulmonary fibrosis |
| "Bleomycin lung" | Classic term for bleomycin-induced pulmonary fibrosis |
| Skin changes | Hypertrophic skin changes, hyperpigmentation of the hands |
| Myelosuppression is RARE | This is unique - unlike most chemo drugs, bleomycin barely suppresses the bone marrow |
Gemcitabine (Figure 35.13 - from your book)
Gemcitabine (2',2'-difluorodeoxycytidine) is a pyrimidine analog shown in your left page.
- Activated by deoxycytidine kinase → becomes the triphosphate form
- Inhibits DNA synthesis
- Used in pancreatic cancer, lung cancer, bladder cancer, breast cancer
Quick Comparison Table
| Drug | Class | Key Use | Unique Toxicity | Myelosuppression? |
|---|---|---|---|---|
| Doxorubicin | Anthracycline | Breast ca, sarcomas, lymphomas | Cardiotoxicity (irreversible) | Yes |
| Daunorubicin | Anthracycline | Acute leukemias | Cardiotoxicity | Yes |
| Idarubicin | Anthracycline | Acute leukemias | Cardiotoxicity (less) | Yes |
| Bleomycin | Antibiotic | Testicular ca, Hodgkin | Pulmonary fibrosis | Rare/No |
High-Yield Exam Points from These Pages
- All antitumor antibiotics = cell cycle NON-specific, EXCEPT bleomycin = G₂ specific
- Doxorubicin's worst toxicity = irreversible cardiotoxicity → use dexrazoxane to protect
- Bleomycin's worst toxicity = pulmonary fibrosis ("bleomycin lung")
- Bleomycin causes myelosuppression rarely - this makes it useful in combination regimens
- Biliary excretion is the main route for anthracyclines - adjust dose in liver disease
- Extravasation with doxorubicin = tissue necrosis (nurse it carefully!)
- Combining doxorubicin + trastuzumab = increased heart failure riskI can see your pages clearly. These cover Alkylating Agents from Lippincott Chapter 35. Let me give you a full simplified breakdown of all three pages.
Alkylating Agents - Simplified from Lippincott (Chapter 35)
What are Alkylating Agents?
Alkylating agents work by covalently bonding to DNA - they attach chemical groups (alkyl groups) to nucleophilic sites on DNA strands, particularly the N-7 position of guanine.
Key Concepts:
- Cell cycle NON-specific - kill both dividing AND resting cells
- Mutagenic and carcinogenic - can cause secondary malignancies (e.g., acute leukemia) - this is a serious long-term risk
- They do NOT discriminate between tumor and normal cells - toxicity to all rapidly dividing cells
- Alkylation = the crucial cytotoxic reaction
A. Cyclophosphamide and Ifosfamide
These are the most commonly used alkylating agents and are very closely related mustard agents.
Clinical Uses:
- Non-Hodgkin lymphoma
- Sarcoma
- Breast cancer
- Wide variety of neoplastic diseases (single agent or combinations)
1. Mechanism of Action
Both are prodrugs activated by the liver:
Cyclophosphamide/Ifosfamide
↓ (CYP450 - liver)
Hydroxylated intermediates
(phosphoramide mustard + acrolein)
↓
Phosphoramide mustard → reacts with DNA
↓
ALKYLATED DNA → cell death
Acrolein is a toxic byproduct responsible for bladder toxicity (see adverse effects).
Memory trick: "Cyclo needs CYP450 to cycle into action"
2. Pharmacokinetics
| Feature | Cyclophosphamide | Ifosfamide |
|---|---|---|
| Route | IV or PO (oral available) | IV only |
| Metabolism | Liver → active + inactive metabolites | CYP450 3A4 and 2B6 isoenzymes |
| Excretion | Minimal unchanged in urine | Mainly renally excreted |
3. Adverse Effects
| Adverse Effect | Notes |
|---|---|
| Hemorrhagic cystitis ⚠️ | Most unique toxicity - caused by acrolein in urine (cyclophosphamide) and toxic metabolites of ifosfamide |
| Prevention | Good hydration + MESNA (sodium 2-mercaptoethane sulfonate) - neutralizes toxic metabolites in bladder |
| Myelosuppression | Bone marrow suppression |
| N/V, alopecia | General chemo toxicities |
| Amenorrhea | Reproductive toxicity |
| Secondary malignancies | Long-term leukemogenic risk |
| Neurotoxicity | Reported with high-dose ifosfamide (due to chloroacetaldehyde metabolite) |
Key exam point: Hemorrhagic cystitis → give MESNA + adequate hydration. MESNA is specifically protective against bladder toxicity, NOT other toxicities.
B. Nitrosoureas: Carmustine (BCNU) and Lomustine (CCNU)
Why are these special?
They cross the blood-brain barrier (BBB) → used primarily for brain tumors
1. Mechanism of Action
- Exert cytotoxic effects by alkylation (like other alkylating agents)
- Also inhibit key enzymatic processes by carbamoylation of amino acids in proteins
- Alkylate DNA in resting cells, but cytotoxicity is mainly expressed in actively dividing cells
- Non-dividing cells can escape if DNA repair occurs
2. Pharmacokinetics
| Feature | Carmustine (BCNU) | Lomustine (CCNU) |
|---|---|---|
| Route | IV (also available as implantable wafer for brain tumors) | PO (oral only) |
| Lipophilicity | High → widely distributed, penetrates CNS | High → same |
| Metabolism | Extensive | Metabolized to active products |
| Excretion | Kidney (major route) | Kidney |
Memory: Carmustine = Chemo wafer (implantable); Lomustine = Let's swallow (oral)
3. Adverse Effects
| Carmustine (BCNU) | Lomustine (CCNU) |
|---|---|
| Myelosuppression | Myelosuppression |
| N/V | N/V |
| Facial flushing | Pulmonary toxicity |
| Hepatotoxicity | Impotence/infertility |
| Pulmonary toxicity | Neurotoxicity |
| Impotence/infertility | Take on empty stomach |
C. Dacarbazine and Temozolomide
Both must be converted to the same active metabolite: MTIC (methyltriazenoimidazole carboxamide)
Shared Mechanism:
MTIC → forms methyl carbonium ions → methylates DNA at O-6 and N-7 positions of guanine → blocks replication
Dacarbazine
- Requires CYP450 for biotransformation to MTIC
- Uses: Melanoma and Hodgkin lymphoma
- Route: IV
- Adverse effects: Myelosuppression, N/V, flu-like syndrome, CNS toxicity, hepatotoxicity, photosensitivity (vesicant!)
Temozolomide
- Does NOT need CYP450 - undergoes chemical transformation at normal physiological pH
- Also inhibits O-6-guanine-DNA alkyltransferase (repair enzyme)
- Crosses the BBB → used for brain tumors (glioblastoma, astrocytoma) + metastatic melanoma
- Route: IV or oral (excellent bioavailability)
- Adverse effects: N/V, myelosuppression, headache, fatigue, photosensitivity
- Special note: Requires Pneumocystis pneumonia prophylaxis
Key difference: Dacarbazine needs CYP450 (liver), Temozolomide does NOT. Temozolomide crosses BBB, dacarbazine does NOT.
D. Other Alkylating Agents
| Drug | Key Use | Unique Points | Unique Toxicity |
|---|---|---|---|
| Mechlorethamine | Lymphatic cancers | First nitrogen mustard (developed in WWI as vesicant) | Vesicant |
| Melphalan | Multiple myeloma | Phenylalanine derivative of nitrogen mustard; dose adjusted by platelet/WBC monitoring | Myelosuppression, mucositis, hypersensitivity (IV) |
| Chlorambucil | Chronic lymphocytic leukemia (CLL) | Bifunctional alkylating agent; take with food | Myelosuppression, pulmonary fibrosis (rare), hyperuricemia, seizures |
| Busulfan | Chronic myelogenous leukemia (CML) | Effective against CML | "Busulfan lung" (pulmonary fibrosis), myelosuppression, hepatotoxicity, mucositis |
Master Summary Table (Figure 35.17 from your book)
| Drug | Route | Key Adverse Effects | Notable Drug Interactions | Notes |
|---|---|---|---|---|
| Cyclophosphamide | IV/PO | Myelosuppression, hemorrhagic cystitis, N/V/D, alopecia, amenorrhea, secondary malignancies | Phenobarbital, phenytoin (CYP450), digoxin, anticoagulants | Good hydration + MESNA with high doses |
| Ifosfamide | IV | Myelosuppression, hemorrhagic cystitis, N/V, neurotoxicity, alopecia, amenorrhea | Phenobarbital, phenytoin, cimetidine, allopurinol, warfarin | Use MESNA + hydration to prevent bladder toxicity |
| Carmustine (BCNU) | IV | Myelosuppression, N/V, facial flushing, hepatotoxicity, pulmonary toxicity, impotence/infertility | Cimetidine, amphotericin B, digoxin, phenytoin | Implantable wafer (brain) available |
| Lomustine (CCNU) | PO | Myelosuppression, N/V, pulmonary toxicity, impotence, neurotoxicity | Cimetidine, alcohol | Give on empty stomach |
| Dacarbazine | IV | Myelosuppression, N/V, flu-like syndrome, CNS toxicity, hepatotoxicity, photosensitivity | Phenytoin, phenobarbital (CYP450) | Vesicant |
| Temozolomide | PO | N/V, myelosuppression, headache, fatigue, photosensitivity | - | Requires Pneumocystis prophylaxis |
| Melphalan | IV/PO | Myelosuppression, N/V/D, mucositis, hypersensitivity (IV) | Cimetidine, steroids, cyclosporine | Take on empty stomach |
| Chlorambucil | PO | Myelosuppression, skin rash, pulmonary fibrosis (rare), hyperuricemia, seizures | Phenobarbital, phenytoin (CYP450) | Take with food |
| Busulfan | IV/PO | Myelosuppression, N/V/D, mucositis, skin rash, pulmonary fibrosis, hepatotoxicity | Acetaminophen, itraconazole, phenytoin | "Busulfan lung" |
High-Yield Exam Points
- Hemorrhagic cystitis = cyclophosphamide/ifosfamide → treat/prevent with MESNA + hydration
- Nitrosoureas (BCNU/CCNU) cross the BBB → brain tumors
- Temozolomide vs Dacarbazine: Same MTIC metabolite, but temozolomide doesn't need CYP450, crosses BBB
- Secondary malignancies = long-term risk with ALL alkylating agents (they are leukemogenic)
- Busulfan lung = pulmonary fibrosis (same pattern as bleomycin lung)
- Carmustine = only alkylating agent available as an implantable wafer (Gliadel) for brain tumors
- Ifosfamide neurotoxicity = caused by chloroacetaldehyde metabolite (high doses)
- Melphalan dose adjusted by monitoring platelets and WBC counts
- All alkylating agents are cell cycle NON-specific - they kill resting cells too
4c4ab101-25b5-4d33-b092-6205d9682673.jpeg
Can u make same mechanism of action for nitrosoureas
I can see your handwritten notes for cyclophosphamide MOA - you want the same style flowchart but for nitrosoureas. Let me generate that now.
Generating Image
A clean handwritten-style study notes diagram on white paper with a clipboard look, titled "M.O.A" in a hand-drawn box at the top, showing the mechanism of action of Nitrosoureas (Carmustine/Lomustine) as a flowchart, matching the style of student handwritten notes: Title box: "M.O.A" Subtitle: "Nitrosoureas (Carmustine BCNU / Lomustine CCNU)" FLOWCHART (downward arrows between each step): Step 1: "Carmustine / Lomustine" (arrow down) Step 2 - box labeled: "Spontaneous chemical decomposition" (no CYP450 needed) (arrow splits into TWO branches) LEFT BRANCH: "Alkylating moiety" ↓ "Reacts with DNA" ↓ "Cross-links DNA strands" (N-7 and O-6 of guanine) ↓ "Alkylated DNA → Cell death" (circle around "Cell death") RIGHT BRANCH: "Isocyanate moiety" ↓ "Carbamoylation of amino acids" ↓ "Inhibits DNA repair enzymes" ↓ "Cell death" (circle) Below the flowchart, a box labeled "PK" with bullet points: • Carmustine → IV (also implantable wafer for brain) • Lomustine → PO only • Lipophilic → cross BBB → used for BRAIN TUMORS • Metabolism: extensive hepatic • Excretion: kidney (major route) Then a box labeled "Adverse": • Myelosuppression • N/V • Carmustine: hepatotoxicity, facial flushing, pulmonary toxicity • Lomustine: neurotoxicity, pulmonary toxicity • Impotence / infertility (both) Hand-drawn style in blue/dark ink on white paper background, same casual student notes aesthetic as a handwritten diagram. Clean, clear, readable.
Here's the nitrosoureas MOA in the same notes style! Here's a quick comparison so you can see how it differs from cyclophosphamide:
| Feature | Cyclophosphamide | Nitrosoureas (BCNU/CCNU) |
|---|---|---|
| Activation | Needs CYP450 in liver | Spontaneous chemical decomposition (no CYP450) |
| Active species | Phosphoramide mustard + Acrolein | Alkylating moiety + Isocyanate moiety |
| DNA attack site | N-7 guanine | N-7 AND O-6 guanine (cross-links) |
| Extra mechanism | Acrolein → bladder toxicity | Isocyanate → carbamoylation → inhibits DNA repair |
| BBB crossing | No | YES → brain tumors |
| Unique toxicity | Hemorrhagic cystitis | Pulmonary toxicity, impotence |
| Protection | MESNA | None specific |
The big advantage of nitrosoureas over cyclophosphamide is exactly this dual mechanism - they both damage DNA directly AND prevent the cell from repairing the damage, making them very effective in brain tumors where other drugs can't reach.
This is a shared conversation. Sign in to Orris to start your own chat.